Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Receivables (2019 - 2025)

Seres Therapeutics' Receivables history spans 5 years, with the latest figure at $404000.0 for Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $404000.0; the TTM value through Sep 2025 reached $404000.0, changed N/A, while the annual FY2024 figure was $6.4 million, N/A changed from the prior year.
  • Receivables for Q3 2025 was $404000.0 at Seres Therapeutics, down from $9.0 million in the prior quarter.
  • Across five years, Receivables topped out at $9.0 million in Q1 2025 and bottomed at $404000.0 in Q3 2025.
  • The 3-year median for Receivables is $1.9 million (2021), against an average of $2.9 million.
  • The largest YoY upside for Receivables was 24.95% in 2021 against a maximum downside of 63.16% in 2021.
  • A 3-year view of Receivables shows it stood at $1.2 million in 2021, then surged by 114.64% to $2.7 million in 2024, then crashed by 84.94% to $404000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Receivables are $404000.0 (Q3 2025), $9.0 million (Q1 2025), and $2.7 million (Q4 2024).